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Keywords: COVID-19, lymphopenia, cancer, radiotherapy, toxicityThe novel human Coronavirus (SARS-CoV-2) pandemic started in late 2019 has killed more than 1
million people worldwide (1). The fatality rate has been linked with a hyperinflammation state
dependent of human interleukin-6 levels and a cytokine-release syndrome (2). This pro-
inflammatory micro-environment can induce lymphocyte-deficiency via apoptosis, impairing
immune-homeostasis, and inflammatory-response (3). Indeed, lymphopenia has emerged as a
major predictor of severe COVID-19 (3). A lymphocyte count <1.5 × 109/L has been associated with
a three-fold increased risk of severe COVID-19 (4). Noteworthy, lymphocytes express Angiotensin-
Converting Enzyme 2 (ACE2) receptor which is exploited by the SARS-CoV-2 to enter host target-
cells, thus representing a possible virus direct target with a subsequent, potentially lethal, lymphatic
organs attack (3).
Cancer treatments can often suppress reservoir lymphoid organs causing lymphopenia, which is
associated with an increased risk of opportunistic infections and worse oncologic outcomes due to
the lymphocytes essential role within the anti-tumor immune response (5). Although chemotherapy
(CT) is often the main trigger of hematologic toxicity (HT), radiotherapy is also a contributing
factor for impairment of hematologic cell lines (6, 7). Lymphocytes are extremely radiosensitive and
show exponential decline early and throughout irradiation (8). The lethal dose required to reduce
the surviving fraction of lymphocytes by 50% (LD50) is only 1.5 Gy, and by 90% (LD90), 3 Gy (9).
Radiation-induced lymphopenia (RIL) has been reported to negatively affect prognosis in several
neoplasms including non-small cell lung cancer (NSCLC), glioblastoma, pancreatic cancer,
esophageal cancer, and head and neck cancers (10–19). Lee et al. evaluated RIL in a cohort of
497 locally advanced pancreatic cancer patients treated with chemoradiation (10). Large
radiotherapy volumes and low baseline lymphocyte count predicted for acute severe
lymphopenia development and recovery. The authors highlighted the importance of severe acute
lymphopenia as it was associated with both poorer overall survival (OS) and progression-free
survival (PFS) (10). For NSCLC, Jin et al. considered the immune system as an organ-at-risk in the
radiotherapy planning. The estimated dose of radiation to circulating immune cells (EDRIC) model
was developed, and a higher EDRIC was associated with not only a greater risk of grade 3 or worse
lymphopenia but also with poorer oncological outcomes (tumor progression and cancer deaths)
within the RTOG-0617 study (12, 13). Tang et al. reported a significant association between lung
low-dose exposure (V1-V5), involving the pulmonary vasculature circulating lymphocytes, and
lymphopenia degree (14). For esophageal cancers, So et al. found that a low lymphocyte nadir was
predictor for OS (hazard ratio = 0.63; p < 0.001) (16). The authors highlighted a significant
correlation between radiation dose to circulating immune cells and the lymphocytes nadir (16).November 2020 | Volume 10 | Article 6173021
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marrow (BM) radiation volumes in esophageal cancers (17).
This is in line with data reported for patients undergoing pelvic
nodal radiotherapy (PNRT), as BM dose-volume parameters have
been associated with the onset of HT, particularly leukopenia (6, 7,
20). Although BM represents only part of the pelvic reservoir
lymphoid organs together with lymph nodes, circulating
lymphocytes, and gut mucosa, radiation-induced BM suppression
is a predictor of leukopenia and lymphopenia (6, 7, 20, 21). BM
stem cells are exquisitely radiosensitive and, in the average adult
population, half of the hematopoietically active BM (aBM) is
located within pelvic bones and lumbar vertebrae (6, 7, 20, 21).
Regarding dosimetric parameters predictive of HT, data from
cervical cancer suggest that volumes receiving low-dose are
important, e.g., pelvic BM V10 < 90%–95% and V20 < 76%–80%
to avoid grade 2-3 HT, especially leukopenia (6, 22). In the RTOG-
0418, which included cervical and endometrial cancer patients, BM
V40 and median BM dose were linked with higher rates of grade 2
or worse HT (23). Techniques to spare BM, like the employment of
PET-guided aBM sparing, have resulted in a significant decrease in
HT, particularly grade 3 or worse neutropenia (24).
Similar to cervical cancer, an association between larger
volumes receiving low-doses and HT emerged from anal
cancer studies (25, 26). Bazan et al. also highlighted the role of
the mean pelvic BM dose as a useful toxicity predictor for anal
cancer patients, recommending a mean dose at <22.5–25 Gy
(25), and supporting the hypothesis of considering the pelvic BM
as a parallel organ when predicting HT (25, 27).
Several studies addressed radiation-induced BM suppression
in rectal cancer patients undergoing PNRT. In a series of 120
rectal cancer patients treated with neoadjuvant pelvic radiotherapy
and concurrent 5-fluorouracil–based CT, Yang et al. found that coxal
BM V45 (p = 0.03) and sacral BM V45 (p = 0.03) were associated
with a lower leukocyte count and lower absolute neutrophil count
ratio at nadir, respectively. Of interest, among all HTs, lymphopenia
occurred most frequently: grade 2 lymphopenia was observed in
97.5% of patients while grade 3 in 56.7% (8).
In amixed population of different pelvic cancers, including rectal,
cervical, anal, vaginal, and bladder cancer patients, McGuire et al.
reported lymphopenia as the most common recorded toxicity (28).
Chronically lower lymphocytes counts (at 1–2 years after
treatment) have been observed in prostate cancer patientsFrontiers in Oncology | www.frontiersin.org 2undergoing PNRT (20, 29). In this regard, Sini et al. highlighted a
higher risk of both acute and late lymphopenia with BM medium-
high doses exposure (≥40Gy) (20).
Accordingly, data of an Italian multicentric study with 406
prostate cancer patients treated with PNRT showed an association
between large nodal volumes (>900 cc) and acute grade 3 or worse
and late grade 2 or worse lymphopenia (lasting at least 1 year)
(29). Thus, prostate cancer radiotherapy is a particularly
interesting scenario for radiation-induced HT studies, given the
increasing use of larger RT volumes to the pelvis.
In times of pandemic, radiation oncologists should be
cautious about utilizing large elective radiation volumes,
particularly when the benefit is uncertain, to avoid suppression
of reservoir lymphoid organs (30). Perhaps short-fractionation
schedules, widely preconized during this outbreak (30), could
have less impact on hematologic counts, particularly extreme-
hypofractionation with steep dose-gradients (11). The low
entrance-dose and sharp fall-off of proton therapy have been
shown to decrease the RIL risk and severity by minimizing
unintended irradiation to circulating immune cells (31).
Proton therapy offers dosimetric advantages in BM sparing
when delivering PNRT as compared to intensity-modulated
radiotherapy and volumetric arc therapy (32, 33). Therefore,
stereotactic body radiotherapy (SBRT) and proton therapy may
represent promising approaches for “lymphocyte sparing
radiotherapy” (21, 31). Additionally, brachytherapy, given the
favorable dose distribution to normal tissues, should also be kept
in mind for more effective “immune-sparing” radiotherapy
approaches (34–37).
Finally, although there is important evidence addressing
radiation-induced HT and lymphopenia, there is still a great
deal of uncertainty on its long-term oncological implications. In
light of the importance of a normal lymphocyte count during the
COVID-19 pandemic, we face an unprecedented opportunity for
further elucidation of the impact of RIL and “lymphocyte-
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